Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

Archives of General Psychiatry
J KaneH Meltzer


The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptics is a major challenge. Clozapine, an atypical antipsychotic drug, has long been of scientific interest, but its clinical development has been delayed because of an associated risk of agranulocytosis. This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refractory to neuroleptics. DSM-III schizophrenics who had failed to respond to at least three different neuroleptics underwent a prospective, single-blind trial of haloperidol (mean dosage, 61 +/- 14 mg/d) for six weeks. Patients whose condition remained unimproved were then randomly assigned, in a double-blind manner, to clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d) for six weeks. Two hundred sixty-eight patients were entered in the double-blind comparison. When a priori criteria were used, 30% of the clozapine-treated patients were categorized as responders compared with 4% of chlorpromazine-treated patients. Clozapine produced significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses' Observation Scale for Inpatient Evaluation; this improvemen...Continue Reading


Nov 14, 2013·ACS Chemical Neuroscience·Philip Seeman
Aug 12, 2009·Pharmacogenomics·Giorgio ConsoliAntonello Di Paolo
Jan 19, 2011·Imaging in Medicine·Judy L ThompsonAnissa Abi-Dargham
Feb 22, 2011·Pharmacogenomics·Fayçal MouaffakMarie Odile Krebs
Mar 19, 2009·The Indian Journal of Medical Research·Rajesh Jaco
Jun 4, 2014·Indian Journal of Psychiatry·T S Sathyanarayana Rao, Chittaranjan Andrade
Feb 4, 2014·Psychopharmacology·Jan BrosdaHeinz H Pertz
Jun 12, 2013·Molecular Psychiatry·A K TiwariH Y Meltzer
Sep 16, 2008·L'Encéphale·V Moulier, D Januel
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·H Y MeltzerR Kessler
Nov 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Cyrille SurP Jeffrey Conn
Feb 26, 2000·Forensic Science International : Synergy·V CirimeleB Ludes
Dec 28, 2012·Journal of Religion and Health·M Kemal Irmak
Apr 10, 2014·Evidence-based Mental Health·Markus Dold, Stefan Leucht
Jan 7, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B GrassiS Scarone
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Sangwon F KimSolomon H Snyder
Jul 6, 2014·BioMed Research International·Nevena DivacNatasa Cerovac
Mar 17, 2004·Biological Psychiatry·Mark H CorriganUNKNOWN Sonepiprazole Study Group
Mar 5, 2011·EMBO Molecular Medicine·Matthew CampbellPeter Humphries
Apr 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Lucia R ValmaggiaCees J Slooff
Oct 4, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Stefan LeuchtRolf Engel
Apr 9, 2014·BMC Psychiatry·Stephanie Warnez, Silvia Alessi-Severini
Oct 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·M Campbell, J E Cueva
Oct 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·H Quintana, M Keshavan
Jul 10, 2014·ISRN Psychiatry·Natalia BartolommeiLorenzo Lattanzi
Sep 26, 2013·Schizophrenia Bulletin·Mitsuhiro MiyashitaMasanari Itokawa
Aug 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Joanna Moncrieff
Oct 2, 2012·Annual Review of Medicine·Herbert Y Meltzer
Jul 30, 2014·Journal of Psychiatric Research·Seiya MiyamotoW Wolfgang Fleischhacker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here